[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Your Free 7-Day Premier trial ends on . Extend Your Trial For Another 30 Days. Time remaining
Faster, Cleaner, Better.

Johnson & Johnson (JNJ)

Johnson & Johnson (JNJ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

How Is Amgen’s Stock Performance Compared to Other General Drug Manufacturers

Thousand Oaks, California-based Amgen Inc. (AMGN) is a leading biotechnology company that discovers, develops, manufactures, and delivers innovative biologic medicines for serious diseases. With a market capitalization of approximately $233.8 billion, the company focuses on oncology, inflammation, general medicine, and rare diseases, leveraging human genetics and advanced biologics manufacturing to improve patient outcomes globally.

Companies worth $200 billion or more are generally described as “mega-cap stocks,” and AMGN fits that description, with its market cap exceeding this threshold and reflecting its substantial size, influence, and dominance within the general drug manufacturers industry. Amgen stands out for its strong portfolio of innovative...

Fundamentals

See More
  • Market Capitalization, $K 645,949,056
  • Shares Outstanding, K 2,409,898
  • Annual Sales, $ 94,193 M
  • Annual Income, $ 26,804 M
  • EBIT $ 23,453 M
  • EBITDA $ 30,956 M
  • 60-Month Beta 0.24
  • Price/Sales 6.80
  • Price/Cash Flow 18.82
  • Price/Book 7.54

Options Overview Details

View History
  • Implied Volatility 24.28% (+0.57%)
  • Historical Volatility 20.81%
  • IV Percentile 72%
  • IV Rank 60.06%
  • IV High 30.74% on 07/07/26
  • IV Low 14.56% on 09/03/25
  • Expected Move (DTE 4) 4.56 (1.71%)
  • Put/Call Vol Ratio 1.00
  • Today's Volume 7,300
  • Volume Avg (30-Day) 26,117
  • Put/Call OI Ratio 0.76
  • Today's Open Interest 367,820
  • Open Int (30-Day) 391,071
  • Expected Range 261.93 to 271.05

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/26
See More
  • Average Estimate $2.95
  • Number of Estimates 6
  • High Estimate $3.14
  • Low Estimate $2.49
  • Prior Year $2.80
  • Growth Rate Est. (year over year) +5.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
250.44 +6.33%
on 08/04/26
276.47 -3.68%
on 08/19/26
+9.95 (+3.88%)
since 07/31/26
3-Month
220.84 +20.59%
on 06/01/26
276.47 -3.68%
on 08/19/26
+40.97 (+18.18%)
since 05/29/26
52-Week
173.33 +53.64%
on 09/19/25
276.47 -3.68%
on 08/19/26
+90.85 (+51.78%)
since 08/28/25

Most Recent Stories

More News
How Is Amgen’s Stock Performance Compared to Other General Drug Manufacturers

AMGN has outperformed the broader market over the past year, while analysts remain moderately bullish on its future prospects.

PJP : 127.33 (+0.06%)
JNJ : 265.79 (-0.84%)
AMGN : 430.29 (-0.49%)
How Is AbbVie’s Stock Performance Compared to Other Healthcare Stocks

AbbVie has underperformed the healthcare peers over the past year, and analysts remain very optimistic about the stock’s outlook.

XLV : 170.52 (-0.37%)
JNJ : 265.79 (-0.84%)
ABBV : 257.53 (+0.80%)
Johnson & Johnson Stock: Is JNJ Outperforming the Consumer Staples Sector?

Johnson & Johnson has outpaced the consumer staples sector over the past year, while analysts remain moderately bullish on the stock’s prospects.

JNJ : 265.79 (-0.84%)
LLY : 1,157.82 (-1.43%)
XLP : 84.97 (-0.56%)
Forget Nvidia. Johnson & Johnson and 2 Other AI Stocks Are Beating the Market by 29 Points.

JNJ, MRK, and AMGN use AI to speed drug discovery, beat the market, and pay dividends. See the top AI healthcare pick for 2026.

MRK : 147.41 (-0.63%)
JNJ : 265.79 (-0.84%)
AMGN : 430.29 (-0.49%)
Warren Buffett’s Granddaughter Says He Disowned Her and Twin Sister in a Letter —‘I Have Not Emotionally or Legally Adopted You as a Grandchild…’

Warren Buffett's approach to wealth has always emphasized handing the next generation opportunity rather than a financial empire. Nicole Buffett’s experience shows just how personal that philosophy can...

JNJ : 265.79 (-0.84%)
Is Eli Lilly Stock Outperforming the Dow?

Outpacing the Dow over the past 12 months, Eli Lilly continues to receive a highly bullish outlook from Wall Street analysts, reflecting confidence in the company’s long-term prospects.

JNJ : 265.79 (-0.84%)
LLY : 1,157.82 (-1.43%)
$DOWI : 53,226.53 (-0.62%)
Meta joins a list of corporations that have settled cases for billions of dollars

Tech giant Meta has agreed to pay $17 billion as part of a settlement to end a landmark trial over teen social media addiction, state attorneys general announced Wednesday

META : 574.15 (-0.67%)
BAC : 62.04 (-0.45%)
VZ : 50.21 (+0.22%)
JPM : 355.03 (-0.72%)
$SPX : 7,674.96 (-0.48%)
JNJ : 265.79 (-0.84%)
$DOWI : 53,226.53 (-0.62%)
$IUXX : 29,354.98 (-0.27%)
FDA approves IMAAVY® (nipocalimab-aahu) as first-ever treatment for warm autoimmune hemolytic anemia (wAIHA), representing a landmark advancement for patients

SPRING HOUSE, Pa. , Aug. 24, 2026 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the U.S. Food and Drug Administration (FDA) approval of IMAAVY ®  (nipocalimab-aahu) for the...

JNJ : 265.79 (-0.84%)
VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?

Vanguard offers three dividend ETFs—VIG, VYM, and VYMI—with distinct yields, holdings, and geographic focus, giving income investors varied ways to access dividend-paying stocks.

BLK : 1,153.62 (-0.93%)
AVGO : 369.81 (+0.28%)
JPM : 355.03 (-0.72%)
JNJ : 265.79 (-0.84%)
VTI : 377.61 (-0.46%)
NVS : 152.14 (-1.09%)
VYM : 163.84 (-0.25%)
HSBC : 103.05 (-0.46%)
RY.TO : 282.75 (-0.50%)
VIG : 242.13 (-0.39%)
VOO : 704.22 (-0.43%)
VYMI : 105.08 (+0.01%)
These 3 Low- and Min-Vol ETFs Fend Off Market Jitters

High-volatility environments can spell danger for stocks. These funds cobble together lower-volatility portfolios to protect against market downside.

SPLV : 74.72 (-0.48%)
VFMV : 145.15 (-0.20%)
SMLV : 157.93 (-0.73%)
KO : 88.78 (-0.98%)
JNJ : 265.79 (-0.84%)
DUK : 120.23 (-0.02%)
FE : 45.95 (+0.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among...

See More

Key Turning Points

3rd Resistance Point 273.63
2nd Resistance Point 271.01
1st Resistance Point 269.52
Last Price 265.75
1st Support Level 265.41
2nd Support Level 262.79
3rd Support Level 261.30

See More

52-Week High 276.47
Last Price 265.75
Fibonacci 61.8% 237.07
Fibonacci 50% 224.90
Fibonacci 38.2% 212.73
52-Week Low 173.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.